-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Raises Price Target to $3

Benzinga·03/06/2026 18:42:08
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and raises the price target from $2 to $3.